MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

Impact · against what's priced in

MBX Biosciences provided one-year data from a Phase II open-label extension study for Canvuparatide, its once-weekly PTH replacement therapy for hypoparathyroidism. The update serves as a clinical milestone supporting the drug's long-term viability and patient-friendliness.

MBX+0.20: No priced-in read yet

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

How each ticker is affected

Regeneron: 3 Key Takeaways for Long-Term Investors

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

How each ticker is affected

Regeneron: 3 Key Takeaways for Long-Term Investors

Track these names every morning.

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Anthropic's IPO push includes a big bet on life sciences

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

How each ticker is affected

Next reads from the same story arc

Regeneron: 3 Key Takeaways for Long-Term Investors

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

How each ticker is affected

Next reads from the same story arc

Regeneron: 3 Key Takeaways for Long-Term Investors

Track these names every morning.

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Anthropic's IPO push includes a big bet on life sciences